C

Carolina Eyecare Physicians | Mount Pleasant, SC

Research site

(Unclaimed)

Location

1101 Clarity Road, Mount Pleasant, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Prednisolone acetate

Ranibizumab

KPI-121

Gatifloxacin

Moxifloxacin HCl

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 23 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting

Diabetic Retinopathy

Drug: Intravitreal Ranibizumab 0.5 mg Injection

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Clareon PanOptix Pro vs. Clareon PanOptix - Study A

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™...

Enrolling

Presbyopia

Aphakia

Procedure: Cataract surgery

Device: CPO IOL

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.

Enrolling

Cataract

Aphakia

Device: Control IOL

Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD)

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection